Both erectile dysfunction (ED) and vascular disease share the same risk factors and the two conditions often coexist, with endothelial dysfunction being the common underlying pathophysiology. Up to two-thirds of all patients with clinically evident coronary artery disease (CAD) have ED. Because of their smaller size, the same degree of lipid plaque burden has a greater effect on the penile arteries compared with the coronary arteries. As a result, the clinical consequences of penile vascular disease (ED) frequently manifest 2-3 years before the consequences of coronary atherosclerosis. This phenomenon has led to the widespread view that ED is a silent marker of vascular disease, particularly CAD, in otherwise asymptomatic men. The Second Princeton Consensus Guidelines reflect this by stating that a man with ED and no cardiac symptoms should be considered a cardiac (or vascular) patient until proven otherwise. For most men with no cardiac symptoms, we therefore have 2-3 years from ED onset to reduce the risk of a cardiovascular event. This article discusses the rationale for the link between ED and CAD, with reference to endothelial dysfunction, and the role of ED as an important means of identifying men at risk of vascular disease.
Introduction
Erectile dysfunction (ED) is a common disorder affecting more than 150 million men worldwide, and more than 50% of men aged 40-70 years in the United States. 1, 2 The incidence of ED increases with age, with men aged 470 years being three times more likely to have ED than men in their forties. 1 A similar age-related pattern also exists for the development of atherosclerosis. Moreover, there is a large body of evidence suggesting that ED is predominantly a vascular disease. It can be noted that both ED and coronary artery disease (CAD) have the same risk factors, namely hypertension, hypercholesterolemia, diabetes, obesity, sedentary lifestyle, depression and smoking. 3 Both conditions are also characterized by having endothelial dysfunction as a common pathophysiology. 4 The recognition that ED and CAD frequently coexist has led to the now widely accepted theory that ED is not just a consequence of vascular disease, but also a silent marker of CAD in otherwise asymptomatic men. 5, 6 This article discusses the rationale for the link between ED and CAD, with reference to endothelial dysfunction, and the role of ED as an important new means of identifying men at risk of vascular disease.
Endothelial dysfunction: a common denominator between ED and vascular disease
The endothelium is a major regulator of vascular homeostasis, producing several signaling molecules, most notably nitric oxide, which promotes vasodilation, inhibits platelet aggregation/adhesion and exerts antifibrotic effects. 7 Endothelial dysfunction is characterized by an increased permeability to plasma constituents including low-density lipoproteins and impaired nitric oxide synthesis/degradation. Such events lead to vasoconstriction, platelet aggregation and white blood cell adhesion. Consequently, endothelial dysfunction is considered to be an early marker of vascular disease, contributing to the development of atherosclerotic lesions and later clinical complications. 7 An association between reduced endothelial response and ED was reported in a study of men with type II (non-insulin-dependent) diabetes mellitus and symptomatic ED. For example, both blood pressure and platelet aggregation (markers of endothelial function) were found to be significantly reduced (in response to L-arginine, a test to assess endothelial function) in men with symptomatic ED (n ¼ 30) compared with those without ED (n ¼ 30). 8 The link between endothelial dysfunction, ED and vascular disease is described in more detail in the earlier article in this supplement authored by Dr Giuliano.
ED as a silent marker for vascular disease: the artery size hypothesis The artery size hypothesis has been used to explain how ED acts as a silent marker of vascular disease elsewhere in the body, and more significantly as a marker of CAD. Artery size varies considerably according to location within the vascular system. For example, the lumen of the penile arteries is considerably smaller (1-2 mm) compared with that of the coronary (3-4 mm), carotid (5-7 mm) and femoral (6-8 mm) arteries. 5 Because of their smaller size, the same level of plaque burden and/or endothelial dysfunction has a greater effect on blood flow through the penile arteries than through the coronary, carotid and femoral arteries (Table 1) . Therefore, the clinical manifestation of penile atherosclerosis, that is ED, becomes evident before the consequences of coronary (for example, CAD), carotid (for example, transient ischemic attack, stroke) and femoral artery (for example, claudication) atherosclerosis. 5 The lumen of the larger arteries become significantly obstructed (450%) only when atherosclerosis intensifies; when this stage is reached, the penile blood flow may have already decreased considerably.
Thus, on the basis of artery size hypothesis and the fact that the endothelium is the same throughout the arterial tree, a malfunction in the penile arteries causing ED may be a predictor of silent subclinical cardiovascular disease (CVD). Furthermore, because an acute coronary syndrome often arises as the result of the rupture of a subclinical plaque, the presence of ED may also be an early warning sign of an acute event as well as being a manifestation of advanced obstructive CAD. 5 
ED as a predictor of CAD
Large population-based studies investigating the incidence of silent CVD in patients with ED have yet to be conducted. However, incidence data are available for patients with clinically evident CAD and suggest that between one-half and two-thirds of all patients with CAD have ED.
In an interview-based study of 300 men with angiographically-documented CAD (mean age 62.5 years), ED was diagnosed in 147 patients (49%) on the basis of the erectile function domain score of the International Index of Erectile Function (IIEF). 10 Other studies have estimated the incidence of ED in patients with CAD to be 65-75%. [11] [12] [13] ED is also more frequent in diabetic patients with silent CAD than in those without. In a study of men with type II diabetes (n ¼ 260), the incidence of ED (IIEF questionnaire) was significantly higher in the population with asymptomatic CAD than in the population without CAD (33.8 vs 4.7%; Po0.0001). ED not only predicted CAD independently of other risk factors but also was the strongest predictor of silent CAD in this study. 14 As already described in detail in Dr Giuliano's article in this supplement, the large Prostate Cancer Prevention Trial provided the first evidence of a strong association between ED and the subsequent development of clinical cardiovascular events. ED at entry or that developed during follow-up was found to significantly predict any cardiac event with a hazard ratio of 1.45 (Po0.001; 95% confidence interval (CI): 1.25-1.69). The data also showed that the cardiovascular risk associated with incident ED (that is, developed during follow-up) was at least as great as the risk associated with a family history of myocardial infarction, current smoking or hypercholesterolemia. 15 A similar strong correlation between ED and increased cardiovascular risk was also reported in a health screening project using the IIEF-5 questionnaire. In this analysis of 2561 patients, the presence of moderate to severe ED (IIEF-5 score 5-16) was calculated to increase the 10-year relative risk of developing CAD by 65% (Po0.001) and of stroke by 43% (P ¼ 0.04). 16 Although mild ED (IIEF-5 score 17-21) was associated with increased risk (18-24%), this observation was not statistically significant.
In a recently reported population-based study (the Krimpen study), a single question on erectile rigidity (from the International Continence Society male sex questionnaire) was shown to be a predictor for the combined outcome of acute myocardial infarction, stroke and sudden death, independently of risk factors in the Framingham risk profile. 17 Men (aged 50-75 years; free of prostate and bladder disease) were followed up for an average of 6.3 years. Of those men who did not have CVD at baseline (n ¼ 1248), 258 (22.8%) had reduced Correlation between ED and extent of CAD
As well as being a predictor for CAD, available data suggest that ED severity is correlated with the extent of CAD; that is, patients with multi-vessel CAD are more likely to have more severe ED compared with those with single-vessel disease. In a questionnairebased study of 40 male patients (mean age 56.6 years) with ischemic heart disease undergoing coronary angiography, a statistically significant correlation was reported between erectile function and the number of coronary vessels involved. Fifteen patients were found to have angiographicallyconfirmed one-vessel disease and 25 patients had two-or three-vessel disease. Patients with one-vessel disease had significantly more (Po0.04) and firmer erections (Po0.001) with fewer difficulties in achieving an erection (Po0.007) than men with two-or three-vessel disease (Figure 1 ). 18 The COBRA (AssoCiatiOn Between eRectile dysfunction and coronary Artery disease) study included an evaluation of the relationship between ED and coronary atherosclerosis, according to coronary clinical presentation and atherosclerosis burden (assessed by the Gensini score), in patients with angiographically documented CAD. 19 The study results showed that ED prevalence for patients with one-vessel disease was significantly higher in patients with chronic compared with acute coronary syndromes (67 vs 22%; Po0.0001). This observation reflects the greater atherosclerotic burden among patients with chronic disease. The association between ED severity and the degree of atherosclerosis was also highlighted in this study; that is, severe ED (IIEF score o10) was significantly more frequent in patients with multi-vessel than in those with single-vessel disease (31 vs 12.5%; Po0.01).
Solomon et al. 12 investigated the prevalence and severity of ED and its relation to the degree of plaque burden in a cohort of 132 men undergoing coronary angiography. Thirty percent of patients were found to have single-vessel disease, 21% had two-vessel disease and 27% had three-vessel disease. There was no significant difference between the number of diseased arteries observed and the incidence of ED (P ¼ 0.34). However, the erectile function score (assessed by IIEF) was significantly correlated with cardiovascular risk factors (r ¼ 0.54; Po0.001) and with the atherosclerotic disease burden (r ¼ 0.44; Po0.001) as assessed by the Gensini score.
Temporal relationship between ED and CAD
Recent findings suggest that there is a strong temporal relationship between ED and CAD, with ED preceding a cardiovascular event by at least 2-3 years. This temporal relationship was investigated in a questionnaire-based study that included 207 patients with CVD attending cardiovascular rehabilitation programs and 165 age-matched controls from general practice in the United Kingdom. 13 Patients completed up to four questionnaires including the IIEF. Of the individuals with CVD, 56% were experiencing symptoms of ED at the time of the study and had done so for a mean of 5 ± 5.3 years. In contrast, 37% of individuals in the control group had ED symptoms for a mean of 6.6 ± 6.8 years. Of particular concern, the study highlighted that only 53% of the CVD group and 43% of the control group had actually discussed their ED symptoms with a health professional.
In a study of 147 men presenting with acute coronary syndrome (plaque rupture), documented ED and CAD, Montorsi et al. 10 reported the presence of clinically evident ED symptoms in 99 patients (67%) developed approximately 3 years (mean 38.8 months, range 1-168 months) prior to the acute event.
In the subsequent COBRA trial, 93% of patients with a chronic coronary syndrome reported ED symptoms before the onset of angina pectoris, with a mean interval of 24 (range 12-36) months. This finding further reinforces the concept of lead time of at least 2-3 years between the development of ED and symptomatic CAD. 19 The time intervals (range) for patients with one-, two-and three-vessel disease were 12 (9.5-24), 24 (16.5-36) and 33 (21-47) months, respectively. There was a significant relationship
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between the length of time from ED to CAD onset and the number of vessels involved (P ¼ 0.016) (Figure 2) . Importantly, given that men with ED may be at cardiovascular risk, this 'long' lead time provides an early opportunity for cardiovascular risk reduction.
Cardiovascular risk reduction in patients with ED
Currently, there are no long-term follow-up data confirming that intervention reduces the risk of developing symptomatic CAD in men with ED. However, the findings from two major cardiovascular studies, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Collaborative Diabetes Atorvastatin Study (CARDS) may serve as a useful guide to risk reduction intervention in men with ED until such data become available. 20, 21 Both studies showed that men of similar age and cardiovascular risk benefit significantly from cardiovascular risk reduction.
The large, randomized ASCOT study (n419 000) tested the primary hypothesis that a newer antihypertensive treatment regimen (calcium channel blocker ± an angiotensin-converting enzyme inhibitor) is more effective than an older regimen (b-blocker ± diuretic) in the primary prevention of coronary heart disease in patients with at least three prespecified cardiovascular risk factors. 20 The second primary hypothesis evaluated whether lipid-lowering therapy with atorvastatin would provide further benefit against coronary heart disease end points in asymptomatic, well-controlled hypertensive patients who were not considered dyslipidemic (total cholesterol p6.5 mmol/l). 22 Although follow-up was planned for a mean of 5 years, the lipid arm of the study was terminated early after a median follow-up of 3.3 years because of a highly significant reduction in the incidence of non-fatal myocardial infarction and fatal coronary heart disease (combined primary end point) and stroke. 22 At the time of study termination, 100 primary events had occurred in the atorvastatin group compared with 154 events in the placebo group (hazard ratio 0.64; 95% CI: 0.50-0.83; P ¼ 0.0005), and 89 cases of fatal and non-fatal stroke had been reported with atorvastatin compared with 121 cases in the placebo group (hazard ratio 0.73; 95% CI: 0.56-0.96; P ¼ 0.024).
In common with ASCOT, CARDS was also stopped 2 years early at 3.9 years, for similar reasons. CARDS was a randomized, double-blind, placebo-controlled trial designed to evaluate statin therapy for primary prevention of CVD in patients with type II diabetes, without elevated low-density lipoproteins cholesterol (n ¼ 2838). The results showed a 37% reduction in the incidence of major cardiovascular end points, and a 48% reduction in the incidence of stroke. 21 A reduction in the primary end point of major CVD events was apparent and statistically significant as early as 18 months after treatment initiation. 23 Although both ASCOT and CARDS did not include ED as a risk factor, given the numbers evaluated, it is highly likely that ED coexisted in a significant number of men enrolled in the two studies, highlighting the importance of cardiovascular risk reduction in men with ED.
Exercise electrocardiography or cardiac-computed tomography? Exercise electrocardiography (ECG) has been widely advocated for the identification of ED patients with an increased cardiovascular risk. However, this procedure has limitations in that it can only be used to identify flow-limiting lesions. Consequently, exercise tolerance tests are often normal in patients in the early stages of atherosclerosis. This limitation means that subclinical lipid-rich plaques that have the potential to rupture and precipitate an acute cardiac event frequently go unidentified.
Findings from a recent study indicate that multidetector computed tomography (MDCT) may be able to address this shortcoming and be used to identify early subclinical plaque disease in patients with normal maximal exercise tests. 24 In this study, 20 men aged 39-69 years with ED and no cardiac symptoms were evaluated. ED was confirmed using the Sexual Health Inventory for Men questionnaire. Eight patients were hypertensive and controlled on medication, 18 patients had elevated low-density lipoproteins cholesterol levels (43.0 mmol/l) and nine patients had a waist circumference X94 cms. Coronary calcium scores exceeded 50 in 11 men (range 54-1234). All of these 11 patients had significant non-obstructive angiographically confirmed CAD on MDCT. However, 9 of these 11 patients had normal maximal exercise ECGs. A particularly noteworthy fact was that one of the men (age 50 years; Sexual Health Inventory for Men score of 16, calcium score 1234) with a significantly abnormal MDCT was able to exercise for 13 min and 26 s to a heart rate of 173 b.p.m with no chest pain and no ECG changes. Another four men in the study had low calcium scores (o20), single plaque disease and normal exercise ECGs. Five patients had normal MDCT scans and were diagnosed as having ED of a predominantly psychologic origin.
Where do we go from here?
With the recognition that ED is an early warning sign for silent coronary and vascular disease, screening for men presenting with ED and no cardiac symptoms is widely advocated. 25, 26 According to the second Princeton Consensus Guidelines, all men with ED and no cardiac symptoms should be considered as cardiac (or vascular) patients until proven otherwise. Such patients should undergo a full medical assessment with stratification of cardiovascular risk as high, medium or low. 25 Those patients at low risk should receive lifestyle advice regarding physical activity and weight control and undergo regular monitoring by their general practitioner. Patients at increased risk for cardiovascular events should ideally undergo stress testing and referral for risk reduction therapy. 26 Although exercise ECG is advocated to identify patients at increased cardiovascular risk, this method will identify only those people with obstructing flow-limiting CAD. Wherever possible, intermediate and high-risk patients should be considered for elective computed tomography coronary angiography to identify the presence of non-flow limiting lipid plaques that are potentially vulnerable to rupture. By implementing these measures, it should be possible to initiate early aggressive cardiovascular risk reduction in 'at-risk' patients, thereby taking advantage of the 2-to 3-year window of opportunity between the development of symptomatic ED and CAD. However, for the full potential of this approach to be realized, comprehensive education programs are required to encourage men with ED to present to their general practitioner as soon as possible. In addition, a multidisciplinary approach is required, involving teamwork between the family doctor, nurse, urologist and cardiologist.
Conclusions
When cardiac risk factors are considered in isolation, the ability to differentiate between those individuals who will or will not develop a cardiovascular event is limited. The reasons for this include the impact of protective factors such as a well-balanced diet, genetic susceptibility and clustering of risk factors (for example, hypertension and diabetes). Furthermore, the coexistence of two or more risk factors can have a profound impact on cardiac risk because their combined effect is often multiplicative rather than just additive. 27 Therefore, to achieve the best results from cardiovascular prevention strategies, it is essential for the medical community to move away from the treatment of risk factors in isolation and toward a comprehensive cardiovascular risk management program.
One cardiovascular risk factor that has come to the forefront in recent years is ED. It is now widely accepted that ED and CAD often coexist and that ED is a silent marker for asymptomatic CAD. ED is an important risk factor for vascular disease, independently adding to and worsening conventional risk factors. ED also has the advantage that, in contrast to other risk factors, it is easy to recognize and adversely affects the quality of life. Therefore, ED is a driving force for some patients to seek medical advice and ultimately receive appropriate risk reduction therapy. The occurrence of ED before CAD offers an average 2-to 3-year window of opportunity to reduce or prevent a coronary event. Not seizing this chance would be a significant missed opportunity in the fight against CVD.
